Form 4: Director Hans Wigzell Acquires Sarepta Therapeutics Shares

Director Hans Wigzell was granted 16,875 restricted stock units in Sarepta Therapeutics, Inc.

Summary

• Director Hans Wigzell acquired 16,875 restricted stock units (RSUs) of Sarepta Therapeutics, Inc. (SRPT) on June 4, 2026.
• Each RSU represents the right to receive one share of common stock.
• Following this transaction, the reporting person's total beneficial ownership is 42,098 shares of common stock.
• The RSUs vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Director alignment with shareholder interests through equity-based compensation.

Negatives

• None.

Risks

• Standard market risks associated with equity ownership in a biotechnology company.

Future Outlook

The RSUs are scheduled to vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that director equity grants are standard corporate governance practices in the biotechnology sector to ensure long-term alignment between board members and shareholders.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation practices for mid-to-large cap biotechnology firms.

Stakeholder Impact

• Increased alignment between the board of directors and shareholders.

Next Steps

• Vesting of the 16,875 RSUs on the earlier of the one-year anniversary or the next annual meeting.

Key Dates

Keywords

Sarepta Therapeutics, SRPT, Form 4, Insider Trading, Director Equity, Biotech